Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 89, 90-98
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Posttranscriptional Regulation of Insulin Family Ligands and ReceptorsInternational Journal of Molecular Sciences, 2013
- L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter EvaluationJNCI: Journal of the National Cancer Institute, 2013
- Comparison of Survival Outcomes Between Patients With Malignant Mixed Mullerian Tumors and High-Grade Endometrioid, Clear Cell, and Papillary Serous Endometrial CancersInternational Journal of Gynecological Cancer, 2011
- High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and OutcomesInternational Journal of Gynecological Pathology, 2010
- IMP3 Distinguishes Uterine Serous Carcinoma From Endometrial Endometrioid AdenocarcinomaAmerican Journal of Clinical Pathology, 2010
- Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlationsLaboratory Investigation, 2007
- Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometriumGynecologic Oncology, 2004
- Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinomaCancer, 2004
- The Reproducibility of a Binary Tumor Grading System for Uterine Endometrial Endometrioid Carcinoma, Compared with FIGO System and Nuclear GradingOncology, 2004
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983